Hypertensive crisis adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From January 2004 to June 2026, FDA received 10,967 adverse event reports that record the MedDRA preferred term Hypertensive crisis. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 549 reports in the 12 months to June 2026 and 487 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 937 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 549 (under 0.1%) record this term. Reports for patients aged 45 to 64 were 28.4% of the reports that record this term and 20% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 137 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Hypertensive crisis name as a suspect product, in order of name
Drug	Class	Reports with this term
Abatacept	Selective T cell costimulation modulator	35
Abilify	Atypical antipsychotic	38
Acetylsalicylic Acid		27
Adalimumab	Tumor necrosis factor blocker	76
Amlodipine	Calcium channel blocker	312
Amlodipine Besilate		35
Apixaban	Factor Xa inhibitor	32
Aripiprazole	Atypical antipsychotic	32
Aspirin	Nonsteroidal anti-inflammatory drug	45
Atenolol	beta-Adrenergic blocker	113
Atorvastatin		32
Avandia		44
Avastin	Vascular endothelial growth factor inhibitor	141
Betmiga		42
Bevacizumab	Vascular endothelial growth factor inhibitor	125
Bisoprolol	beta-Adrenergic blocker	99
Bisoprolol fumarate	beta-Adrenergic blocker	52
Candesartan	Angiotensin 2 receptor blocker	31
Capecitabine	Nucleoside metabolic inhibitor	40
Carboplatin	Platinum-based drug	109
Cardura	alpha-Adrenergic blocker	54
Carfilzomib	Proteasome inhibitor	35
Carvedilol	alpha-Adrenergic blocker	64
Cimzia	Tumor necrosis factor blocker	30
Cisplatin	Platinum-based drug	25
Clonidine	Central alpha-2 adrenergic agonist	113
Cosentyx	Interleukin-17A antagonist	38
Cyclophosphamide	Alkylating drug	30
Cyclosporine	Calcineurin inhibitor immunosuppressant	71
Cymbalta		52
Darzalex	CD38-directed cytolytic antibody	28
Dexamethasone	Corticosteroid	117
DIANEAL PD-2 with Dextrose	Osmotic laxative	50
Diclofenac	Nonsteroidal anti-inflammatory drug	38
Diovan	Angiotensin 2 receptor blocker	90
Diovan HCT	Angiotensin 2 receptor blocker	28
Doxazosin	alpha-Adrenergic blocker	79
Duloxetine	Serotonin and norepinephrine reuptake inhibitor	35
Eliquis	Factor Xa inhibitor	41
Enalapril	Angiotensin converting enzyme inhibitor	66
Enbrel	Tumor necrosis factor blocker	83
Enzalutamide	Androgen receptor inhibitor	28
Epinephrine	Catecholamine	27
Erelzi		26
Etanercept	Tumor necrosis factor blocker	38
Exforge	Angiotensin 2 receptor blocker	41
Exforge HCT	Angiotensin 2 receptor blocker	30
Fentanyl	Opioid agonist	45
Fluorouracil	Nucleoside metabolic inhibitor	109
Fulvestrant	Estrogen receptor antagonist	35
Furosemide	Loop diuretic	55
Gabapentin	Anti-epileptic agent	38
Gilenya	Sphingosine 1-phosphate receptor modulator	49
Humira		198
Hydralazine		35
Hydrochlorothiazide	Thiazide diuretic	89
Hydroxychloroquine	Antimalarial	46
Hydroxychloroquine sulfate	Antimalarial	36
Ibuprofen	Nonsteroidal anti-inflammatory drug	87
Imbruvica	Kinase inhibitor	44
Infliximab	Tumor necrosis factor blocker	31
Irbesartan	Angiotensin 2 receptor blocker	56
Irinotecan		51
Keytruda	Programmed death Receptor-1 blocking antibody	27
Kisqali	Kinase inhibitor	83
Kyprolis	Proteasome inhibitor	30
Lantus	Insulin analog	41
Lasix	Loop diuretic	63
Leflunomide	Antirheumatic agent	51
Lenvima	Kinase inhibitor	55
Letrozole	Aromatase inhibitor	81
Lidocaine	Amide local anesthetic	31
Lisinopril	Angiotensin converting enzyme inhibitor	68
Losartan	Angiotensin 2 receptor blocker	69
Losartan potassium	Angiotensin 2 receptor blocker	33
Lyrica		34
Mabthera		31
Metformin	Biguanide	42
Methotrexate	Folate analog metabolic inhibitor	248
Methotrexate sodium	Folate analog metabolic inhibitor	48
Metoprolol	beta-Adrenergic blocker	99
Metoprolol succinate	beta-Adrenergic blocker	30
Micardis		31
Mirtazapine		31
Myrbetriq	beta3-Adrenergic agonist	25
Nardil	Monoamine oxidase inhibitor	29
Nebivolol	beta-Adrenergic blocker	49
Nifedipine	Dihydropyridine calcium channel blocker	49
Norvasc	Calcium channel blocker	118
Olmesartan medoxomil	Angiotensin 2 receptor blocker	54
Omalizumab	Anti-IgE	27
Orencia	Selective T cell costimulation modulator	39
Oxaliplatin	Platinum-based drug	211
Paclitaxel	Microtubule inhibitor	154
Paroxetine	Serotonin reuptake inhibitor	25
Pembrolizumab	Programmed death Receptor-1 blocking antibody	32
Pertuzumab	HER2/neu receptor antagonist	26
Plaquenil	Antimalarial	31
Plavix	P2Y12 platelet inhibitor	25
Pradaxa	Direct thrombin inhibitor	57
Prednisolone	Corticosteroid	64
Prednisone	Corticosteroid	89
Privigen	Human immunoglobulin G	25
Propofol	General anesthetic	26
Propranolol	beta-Adrenergic blocker	27
Quetiapine	Atypical antipsychotic	42
Ramipril	Angiotensin converting enzyme inhibitor	289
Rasilez		41
Rebif	Interferon beta	26
Remicade	Tumor necrosis factor blocker	87
Revlimid	Thalidomide analog	33
Ribavirin	Nucleoside analog antiviral	32
Rifampicin		30
Rinvoq	Janus kinase inhibitor	27
Risperidone	Atypical antipsychotic	27
Rituximab	CD20-directed cytolytic antibody	179
Sertraline	Serotonin reuptake inhibitor	36
Simvastatin	HMG-CoA reductase inhibitor	47
Soliris	Complement inhibitor	52
Spravato		36
Sulfasalazine	Aminosalicylate	54
Sutent	Kinase inhibitor	61
Tacrolimus	Calcineurin inhibitor immunosuppressant	37
Telmisartan	Angiotensin 2 receptor blocker	31
Tocilizumab	Interleukin-6 receptor antagonist	66
Torsemide	Loop diuretic	29
Trastuzumab	HER2/neu receptor antagonist	41
Triatec		73
Valsartan	Angiotensin 2 receptor blocker	152
Venlafaxine	Serotonin and norepinephrine reuptake inhibitor	47
Venlafaxine hydrochloride	Serotonin and norepinephrine reuptake inhibitor	30
Vioxx		91
Votrient	Kinase inhibitor	45
Xarelto	Factor Xa inhibitor	76
Xeljanz	Janus kinase inhibitor	51
Xtandi	Androgen receptor inhibitor	45
Zemplar	Vitamin D analog	34

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 51 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Hypertensive crisis name, in order of name
Class	Reports with this term
alpha-Adrenergic blocker	245
Aminosalicylate	60
Androgen receptor inhibitor	90
Angiotensin 2 receptor blocker	691
Angiotensin converting enzyme inhibitor	463
Anti-epileptic agent	74
Antimalarial	113
Antirheumatic agent	68
Aromatase inhibitor	126
Atypical antipsychotic	220
Benzodiazepine	71
beta-Adrenergic blocker	539
Biguanide	90
Calcineurin inhibitor immunosuppressant	145
Calcium channel blocker	439
CD20-directed cytolytic antibody	217
CD38-directed cytolytic antibody	67
Central alpha-2 adrenergic agonist	159
Central nervous system stimulant	82
Complement inhibitor	66
Corticosteroid	350
Dihydropyridine calcium channel blocker	90
Direct thrombin inhibitor	57
Factor Xa inhibitor	171
Folate analog metabolic inhibitor	303
HER2/neu receptor antagonist	103
HMG-CoA reductase inhibitor	64
Human immunoglobulin G	51
Insulin analog	83
Interleukin-6 receptor antagonist	89
Janus kinase inhibitor	113
Kinase inhibitor	523
Loop diuretic	147
Microtubule inhibitor	178
Monoamine oxidase inhibitor	62
Nonsteroidal anti-inflammatory drug	243
Nucleoside metabolic inhibitor	223
Opioid agonist	121
Osmotic laxative	75
P2Y12 platelet inhibitor	56
Platinum-based drug	345
Programmed death Receptor-1 blocking antibody	110
Proteasome inhibitor	80
Selective T cell costimulation modulator	74
Serotonin and norepinephrine reuptake inhibitor	147
Serotonin reuptake inhibitor	140
Sphingosine 1-phosphate receptor modulator	60
Thalidomide analog	52
Thiazide diuretic	100
Tumor necrosis factor blocker	391
Vascular endothelial growth factor inhibitor	349

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Hypertensive crisis, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Hypertensive crisis
Age	Reports	Share
Under 2	30	0.3%
2 to 11	91	0.8%
12 to 17	62	0.6%
18 to 44	935	8.5%
45 to 64	3,116	28.4%
65 to 74	2,086	19%
75 and over	1,809	16.5%
Age not given	2,838	25.9%

Sex of the patient in the reports that record Hypertensive crisis
Sex	Reports	Share
Female	6,287	57.3%
Male	3,657	33.3%
Unknown or not given	1,023	9.3%

Age and sex are as the report gives them. 17.8% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Hypertensive crisis: adverse event reports that record this term. https://reportedreactions.com/reaction/hypertensive-crisis/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Hypertensive crisis mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page